Pulmonary arterial hypertension
Information
- Disease name
- Pulmonary arterial hypertension
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05818137 | Active, not recruiting | Phase 3 | A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020) | May 10, 2023 | August 13, 2025 |
| NCT02980887 | Active, not recruiting | Pulmonary Vascular Disease Phenomics Program PVDOMICS | November 2016 | December 31, 2029 | |
| NCT04130243 | Active, not recruiting | Biomarkers in Pediatric Congenital Heart Disease and PAH | December 5, 2017 | December 1, 2024 | |
| NCT04416750 | Active, not recruiting | Phase 2 | Positioning Imatinib for Pulmonary Arterial Hypertension | January 20, 2021 | July 1, 2024 |
| NCT04732221 | Active, not recruiting | Phase 2/Phase 3 | A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007) | May 19, 2021 | July 15, 2024 |
| NCT03492177 | Active, not recruiting | Phase 2 | A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension | July 23, 2018 | December 31, 2026 |
| NCT03550729 | Active, not recruiting | N/A | Effects of Physical Training on Vascular Function as a Therapeutic Target in Pulmonary Hypertension | July 1, 2018 | December 2024 |
| NCT02835950 | Active, not recruiting | N/A | TReatment Of Pulmonary HYpertension 1-US Study | March 1, 2017 | December 2023 |
| NCT06092424 | Active, not recruiting | N/A | High Altitude (HA) Residents With Pulmonary Vascular Diseseases (PVD), Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) vs Sea Level (LA) | September 23, 2023 | December 31, 2024 |
| NCT04744584 | Active, not recruiting | Medication Reconciliation in Pulmonary Hypertension | February 15, 2021 | June 15, 2024 | |
| NCT03288025 | Active, not recruiting | N/A | Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE) | September 27, 2017 | June 30, 2024 |
| NCT03648385 | Active, not recruiting | Phase 2 | Effects of DHEA in Pulmonary Hypertension | January 9, 2019 | December 2024 |
| NCT04813926 | Active, not recruiting | A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH) | July 16, 2021 | December 31, 2025 | |
| NCT03893500 | Active, not recruiting | N/A | Utility of At-home Monitoring of Exercise Capacity by App-based 6-minute Walk Test | July 1, 2020 | June 30, 2025 |
| NCT03045029 | Active, not recruiting | ADAPT - A Patient Registry of the Real-world Use of Orenitram® | July 18, 2017 | December 2023 | |
| NCT01321073 | Active, not recruiting | N/A | DelIVery for Pulmonary Arterial Hypertension (PAH) & Continued Support Study | June 2011 | December 2032 |
| NCT04896008 | Active, not recruiting | Phase 3 | A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH) | December 1, 2021 | November 28, 2025 |
| NCT05060315 | Active, not recruiting | Evaluate Real-World Use of Next Generation Infusion Pumps to Administer Remodulin | July 5, 2023 | December 31, 2024 | |
| NCT06321705 | Available | Safety and Efficacy of Continued CS1 Treatment of Patients With Pulmonary Arterial Hypertension | |||
| NCT00581607 | Completed | Phase 2/Phase 3 | Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension | April 2008 | December 2012 |
| NCT00609349 | Completed | N/A | The Early Recognition of Pulmonary Arterial Hypertension | April 2006 | May 2009 |
| NCT00617305 | Completed | Phase 4 | Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1) | April 2008 | July 2011 |
| NCT00621075 | Completed | Correlation OF Hemodynamics in Pulmonary Hypertension With Perfusion Lung Scans | April 2007 | February 2008 | |
| NCT06312111 | Completed | N/A | Physical Activity and Various Aspects of Quality of Life in Patients With Pulmonary Arterial Hypertension (Ph-PAH) | April 22, 2021 | July 17, 2022 |
| NCT00660179 | Completed | Phase 3 | Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension | May 2008 | April 2012 |
| NCT00667823 | Completed | Phase 3 | Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension | October 17, 2008 | December 7, 2020 |
| NCT00705133 | Completed | Phase 2 | Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension | July 2008 | April 2011 |
| NCT06180096 | Completed | Phase 1 | Bioequivalence Study of Riociguat 2.5 mg Film Coated Tablets and Adempas (Riociguat) 2.5 mg Film Coated Tablets | March 7, 2023 | April 6, 2023 |
| NCT00709098 | Completed | Phase 3 | Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension | September 2008 | June 2010 |
| NCT00709956 | Completed | Phase 3 | Iloprost Power 15 in Pulmonary Arterial Hypertension | July 2008 | August 2009 |
| NCT00741819 | Completed | Phase 4 | Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects | September 2008 | December 2010 |
| NCT00781885 | Completed | Phase 2 | A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients | January 31, 2009 | September 30, 2010 |
| NCT00792571 | Completed | Phase 2 | An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients | February 28, 2009 | November 30, 2013 |
| NCT06009185 | Completed | Phase 2 | Safety and Efficacy of BIA 5-1058 in PAH | June 26, 2019 | February 17, 2022 |
| NCT00806312 | Completed | The Expression and Significance of MiRNA | July 2008 | August 16, 2018 | |
| NCT00814645 | Completed | Phase 1 | Dose-Finding, Safety, Pharmacodynamic Effect Study of Sodium Nitrite Inhalation Solution in Normal, Healthy Volunteers | December 2008 | June 2009 |
| NCT05948644 | Completed | Phase 1 | The Safety, Tolerability, and Pharmacokinetics of TPN171H Tablets in Patients With Pulmonary Arterial Hypertension | April 8, 2019 | October 14, 2020 |
| NCT00902174 | Completed | Phase 3 | Imatinib (QTI571) in Pulmonary Arterial Hypertension | September 2009 | May 2011 |
| NCT05947032 | Completed | N/A | Supervised Endurance Training Among Pulmonary Arterial Hypertension Patients | August 20, 2023 | December 1, 2023 |
| NCT00926523 | Completed | Biomarkers in the Evaluation of Chronic Lung Disease | June 2009 | March 2011 | |
| NCT00942708 | Completed | Phase 2 | Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension | September 2009 | August 2011 |
| NCT00963001 | Completed | Phase 1 | Effect of Food on the Pharmacokinetics of Oral Treprostinil | September 2009 | November 2009 |
| NCT00963027 | Completed | Phase 1 | Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil | September 2009 | October 2009 |
| NCT00964678 | Completed | Phase 1/Phase 2 | Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension | June 2010 | May 2014 |
| NCT00989963 | Completed | Phase 2 | Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH) | February 1, 2010 | September 13, 2011 |
| NCT00990314 | Completed | Phase 2 | Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients | November 30, 2009 | November 30, 2013 |
| NCT00993408 | Completed | Phase 2 | Study of ACT-293987 (NS-304) in Pulmonary Arterial Hypertension (PAH) | April 30, 2008 | June 30, 2009 |
| NCT05861479 | Completed | Prognostic Value of Estimated Plasma Volume in Pulmonary Hypertension | January 1, 2015 | April 1, 2023 | |
| NCT01027949 | Completed | Phase 3 | An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension | January 16, 2007 | February 12, 2020 |
| NCT01028651 | Completed | A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension | January 2011 | April 2013 | |
| NCT01042158 | Completed | Phase 4 | A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis | January 2010 | November 2014 |
| NCT01043627 | Completed | Sildenafil to Tadalafil in Pulmonary Arterial Hypertension (SITAR) | December 2009 | December 2011 | |
| NCT01054105 | Completed | Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension | October 2010 | December 25, 2018 | |
| NCT01066845 | Completed | Post Marketing Observational Study in Patients With Pulmonary Arterial Hypertension | January 2010 | August 2014 | |
| NCT01092559 | Completed | Phase 2 | Pilot Study Evaluating the Safety and Performance of the GeNO NITROsyl Delivery System for Inhaled Nitric Oxide | October 2010 | July 2011 |
| NCT05767918 | Completed | StratosPHere (Non-interventional Study) | April 14, 2021 | September 30, 2022 | |
| NCT01100736 | Completed | Early Phase 1 | Role of Endothelin-A (ETA) and Endothelin-B (ETB) Receptors in the Vasodilatory Response to Endothelin-3 (ET-3) | January 2009 | January 2010 |
| NCT01105091 | Completed | Phase 4 | Epoprostenol for Injection in Pulmonary Arterial Hypertension | March 2010 | July 2011 |
| NCT01105117 | Completed | Phase 4 | Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401 | May 2010 | December 2011 |
| NCT01106014 | Completed | Phase 3 | Selexipag (ACT-293987) in Pulmonary Arterial Hypertension | December 1, 2009 | October 1, 2014 |
| NCT01112306 | Completed | Phase 3 | ACT-293987 in Pulmonary Arterial Hypertension | July 7, 2010 | August 26, 2021 |
| NCT05764265 | Completed | Phase 2 | Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants | March 27, 2023 | May 14, 2024 |
| NCT01131845 | Completed | Phase 1 | The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil | May 2010 | September 2010 |
| NCT01148836 | Completed | N/A | Coenzyme Q-10 and Pulmonary Arterial Hypertension | January 2010 | January 2014 |
| NCT01153386 | Completed | Phase 1 | Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine | July 2010 | August 2010 |
| NCT01165047 | Completed | Phase 2 | Nitric Oxide, GeNO Nitrosyl Delivery System | September 2010 | September 2011 |
| NCT01165476 | Completed | Phase 1 | Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent Facilities | July 2010 | August 2010 |
| NCT01172496 | Completed | Phase 1 | A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers | August 2010 | |
| NCT01174173 | Completed | Phase 3 | Ranolazine and Pulmonary Hypertension | June 2010 | October 2014 |
| NCT01181284 | Completed | Modulating Effects of Lisinopril on Sildenafil Activity in Pulmonary Arterial Hypertension(PAH)( MELISSA) | May 2008 | July 2011 | |
| NCT01208792 | Completed | N/A | Auto-immunity and Pulmonary Arterial Hypertension | June 15, 2010 | May 15, 2017 |
| NCT01223352 | Completed | Phase 3 | Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension | March 8, 2011 | August 19, 2013 |
| NCT03365479 | Completed | N/A | Acute Response of Iloprost Inhalation Using the Breelib Nebulizer in Pulmonary Arterial Hypertension | May 1, 2017 | October 24, 2018 |
| NCT03422328 | Completed | Phase 3 | A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies. | April 5, 2018 | December 27, 2023 |
| NCT03464864 | Completed | Phase 1 | Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers | March 9, 2018 | June 5, 2018 |
| NCT03522935 | Completed | Phase 1 | Subcutaneous Elafin in Healthy Subjects | March 18, 2019 | November 18, 2020 |
| NCT03489005 | Completed | Phase 1 | Effect of BIA 5 1058 on Cardiac Repolarization | April 9, 2018 | October 5, 2018 |
| NCT03496207 | Completed | Phase 2 | A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH) | June 13, 2018 | March 9, 2022 |
| NCT03497689 | Completed | Phase 4 | EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension | January 31, 2019 | May 11, 2022 |
| NCT00377949 | Completed | Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients | February 2005 | ||
| NCT00403650 | Completed | Phase 4 | Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension | November 2006 | September 2008 |
| NCT00423202 | Completed | Phase 3 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension. | December 2003 | October 2005 |
| NCT00423748 | Completed | Phase 3 | Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension. | December 2003 | February 2006 |
| NCT00058929 | Completed | Phase 4 | A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension | October 2002 | August 2005 |
| NCT00433329 | Completed | Phase 4 | Combination Therapy in Pulmonary Arterial Hypertension | March 2007 | August 2010 |
| NCT00435331 | Completed | Phase 1 | 6R-BH4 Pulmonary Arterial Hypertension Study | March 2008 | October 2008 |
| NCT00452218 | Completed | Phase 1 | Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH) | March 2007 | May 2012 |
| NCT00477269 | Completed | Phase 2/Phase 3 | Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension | April 2006 | January 2014 |
| NCT00554619 | Completed | Phase 3 | A Study to Evaluate GSK1325760A - a Long-Term Extension Study | February 2008 | January 2011 |
| NCT00566423 | Completed | N/A | Biomarkers in the Diagnosis and Assessment of Pulmonary Arterial Hypertension (PAH) | May 2007 | June 2010 |
| NCT00578786 | Completed | Phase 3 | A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202) | February 2004 | March 2010 |
| NCT03863990 | Completed | Study Performed at Various Medical Centers to Learn More About Survival and Expected Course of Pulmonary Arterial Hypertension, a Type of High Blood Pressure in the Lungs Related to the Narrowing of the Small Blood Vessels in the Lungs | July 15, 2019 | May 11, 2020 | |
| NCT02911844 | Completed | Phase 2 | Estrogen Receptor Antagonist in Patients With Pulmonary Arterial Hypertension | April 10, 2017 | December 5, 2018 |
| NCT03744637 | Completed | Phase 1 | A Study of Single Doses of MK -5475 on Pulmonary Vascular Resistance (MK-5475-002) | January 18, 2019 | December 11, 2020 |
| NCT00367770 | Completed | Phase 4 | BREATHE 5-OL: Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology | January 2004 | December 2005 |
| NCT03738150 | Completed | Phase 2 | A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension | April 19, 2019 | March 22, 2022 |
| NCT03708146 | Completed | Phase 1 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 5-1058 | May 28, 2018 | March 18, 2019 |
| NCT02961023 | Completed | N/A | The Effect of Adding Exercise Training to Optimal Therapy in PAH | February 2016 | July 2018 |
| NCT03688698 | Completed | PET/MRI in PAH Patients | May 1, 2016 | January 1, 2018 | |
| NCT03655704 | Completed | Early Phase 1 | Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study | August 22, 2019 | December 13, 2021 |
| NCT03638908 | Completed | Phase 2 | Fluoxetine in Pulmonary Arterial Hypertension (PAH) Trial | November 2013 | December 2018 |
| NCT03612115 | Completed | N/A | Neuromuscular Electrical Stimulation in Pulmonary Arterial Hypertension | September 1, 2015 | September 28, 2017 |
| NCT03055221 | Completed | Phase 4 | TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH) | June 10, 2005 | February 25, 2014 |
| NCT03057028 | Completed | Phase 1 | Pilot Study of the Safety and Efficacy of Anakinra in Pulmonary Arterial Hypertension | April 2016 | June 7, 2018 |
| NCT03069716 | Completed | N/A | A Mobile Health Intervention in Pulmonary Arterial Hypertension | August 2, 2017 | April 24, 2020 |
| NCT03078907 | Completed | Phase 4 | Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension. | November 8, 2017 | February 10, 2020 |
| NCT03105934 | Completed | N/A | Repeatability of OCT and IV-US in Pulmonary Arterial Hypertension | April 2016 | January 25, 2018 |
| NCT03166306 | Completed | Phase 1/Phase 2 | Angiogenic Imaging in Pulmonary Arterial Hypertension | May 1, 2018 | March 31, 2020 |
| NCT03187678 | Completed | Phase 3 | Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension | December 4, 2017 | May 29, 2018 |
| NCT03197688 | Completed | Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States | August 3, 2017 | September 6, 2018 | |
| NCT03229499 | Completed | Phase 2 | Pulmonary Hypertension and Anastrozole Trial | December 7, 2017 | July 22, 2022 |
| NCT03554291 | Completed | Phase 2 | Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension | May 1, 2019 | July 11, 2023 |
| NCT03278002 | Completed | A Registry for Patients Taking Uptravi | November 1, 2016 | September 21, 2021 | |
| NCT03282266 | Completed | N/A | Safety and Efficacy of Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension | January 18, 2018 | December 22, 2021 |
| NCT03315507 | Completed | Phase 1 | A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH | October 20, 2017 | August 8, 2019 |
| NCT03344159 | Completed | Phase 4 | Spironolactone Therapy in Chronic Stable Right HF Trial | April 1, 2018 | November 30, 2022 |
| NCT03364244 | Completed | Revatio Special Investigation for Long-term Use in Pediatric Patients | November 30, 2017 | August 30, 2022 | |
| NCT03528902 | Completed | Phase 2 | Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension | October 1, 2018 | June 14, 2023 |
| NCT01260454 | Completed | Phase 2 | The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain | November 2010 | April 2012 |
| NCT01265888 | Completed | Phase 2 | Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl. | March 2011 | September 2016 |
| NCT01266265 | Completed | Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies | December 2010 | December 2014 | |
| NCT01268553 | Completed | Phase 4 | Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication | August 2010 | October 5, 2016 |
| NCT01317134 | Completed | N/A | Endothelial Function in Patients With Pulmonary Arterial Hypertension | October 2010 | July 2016 |
| NCT01330108 | Completed | Phase 4 | Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension | May 2011 | June 2012 |
| NCT01338415 | Completed | Phase 3 | FUTURE 3 Study Extension | March 8, 2011 | May 29, 2020 |
| NCT05521113 | Completed | Home-based Pulmonary Rehabilitation With Remote Monitoring in Pulmonary Arterial Hypertension | September 6, 2022 | June 30, 2023 | |
| NCT01355380 | Completed | Efficacy of Ventavis Used in Real-life Setting. | August 5, 2010 | September 22, 2016 | |
| NCT05439460 | Completed | Phase 4 | Management of Acute Pulmonary Hypertensive Crisis in Children With Known Pulmonary Arterial Hypertension | January 2012 | June 2014 |
| NCT01365585 | Completed | Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial Hypertension | July 2011 | October 2011 | |
| NCT05437224 | Completed | Phase 3 | Efficacy and Safety Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension | December 18, 2018 | February 6, 2022 |
| NCT01389206 | Completed | Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program | June 1, 2011 | April 10, 2018 | |
| NCT01391104 | Completed | N/A | Responsiveness of Exercise Tests in Pulmonary Arterial Hypertension | April 2009 | November 2011 |
| NCT01392469 | Completed | Phase 3 | Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants | April 20, 2011 | October 25, 2012 |
| NCT05427162 | Completed | Phase 1 | A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor Agonist | June 21, 2022 | December 5, 2023 |
| NCT00086463 | Completed | Phase 2 | Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH) | June 2004 | January 2006 |
| NCT01409122 | Completed | Phase 1 | Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects | July 2011 | January 2012 |
| NCT05343637 | Completed | Phase 2 | A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension | July 30, 2019 | January 17, 2020 |
| NCT01431326 | Completed | Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care | November 2011 | November 2019 | |
| NCT01431716 | Completed | Phase 3 | Epoprostenol for Injection (EFI/ACT-385781A) - Pulmonary Arterial Hypertension | March 2011 | July 2012 |
| NCT05318950 | Completed | N/A | A nUtrition and Lifestyle Intervention in Patients With Pulmonary Arterial HypertensIon | October 20, 2019 | February 16, 2022 |
| NCT01443598 | Completed | Pulmonary Hypertension in Interstitial Lung Disease | July 2010 | June 2016 | |
| NCT01445873 | Completed | Pilot Chart Review Study Of Sitaxentan Sodium (Thelin) In Patients With Pulmonary Arterial Hypertension (PAH) | December 1, 2009 | March 28, 2011 | |
| NCT01446848 | Completed | N/A | Oral Iron Supplementation in Pulmonary Hypertension | January 2012 | August 2014 |
| NCT01447628 | Completed | Phase 2 | IV Iron Replacement for Iron Deficiency in Idiopathic Pulmonary Arterial Hypertension (IPAH) Patients | March 29, 2011 | December 22, 2017 |
| NCT01451255 | Completed | Early Detection of Pulmonary Arterial Hypertension Using Cardiac Magnetic Resonance Imaging | August 2011 | June 2014 | |
| NCT05242380 | Completed | N/A | Exercise Training in Patients With Pulmonary Arterial Hypertension | June 10, 2022 | September 15, 2023 |
| NCT01457781 | Completed | Phase 2 | Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH) | April 2012 | July 2016 |
| NCT05208814 | Completed | Phase 1 | a Study to Evaluate the Pharmacokinetics and Safety of TPN171H Tablets in Patients With Renal Insufficiency and Healthy Subjects | March 31, 2022 | October 25, 2022 |
| NCT01461343 | Completed | N/A | Evaluation of Pulmonary Perfusion Heterogeneity and Compliance in Patients With Pulmonary Hypertension Using Positron Emission Tomography Imaging | February 2013 | March 15, 2018 |
| NCT01468545 | Completed | Educational Training Influence in Patients With PAH(Pulmonary Artery Hypertension) on Inhaled Ventavis Treatment Adherence Evaluated Trough INSIGHT System | October 2011 | June 2014 | |
| NCT01470144 | Completed | Phase 3 | Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension | June 1, 2011 | July 1, 2015 |
| NCT01477333 | Completed | Phase 2 | Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso® | October 2011 | November 2013 |
| NCT01484431 | Completed | Phase 1/Phase 2 | A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension | July 17, 2012 | April 3, 2019 |
| NCT05185011 | Completed | Phase 1 | Study of the Pharmacokinetics and Safety of TPN171H Tablets in Subjects With Mild ,Moderate Hepatic Insufficiency and Normal Liver Function | December 16, 2021 | February 6, 2022 |
| NCT01496963 | Completed | Prevalence of Pulmonary Hypertension (PAH) in Patients With Thalassemia | January 2012 | December 2021 | |
| NCT05135000 | Completed | Phase 2 | Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension | June 30, 2022 | April 25, 2024 |
| NCT01520493 | Completed | N/A | Peripheral Muscle Microcirculation and Exercise-induced Blood Flow Distribution in Pulmonary Arterial Hypertension | June 2011 | March 2015 |
| NCT01545336 | Completed | Phase 2 | Anastrozole in Patients With Pulmonary Arterial Hypertension | October 2012 | September 2015 |
| NCT01548950 | Completed | N/A | Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension | September 2011 | March 2020 |
| NCT01553721 | Completed | Phase 2 | Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH) | August 2011 | March 2015 |
| NCT01557582 | Completed | N/A | Assessmet of Patients With PAH Right Ventricular Volume | April 2012 | December 2013 |
| NCT05124015 | Completed | Exercise Capacity Respiratory Muscle Strength Dyspnea and Physical Activity in Pediatric Pulmonary Arterial Hypertension | November 10, 2019 | October 10, 2021 | |
| NCT01560624 | Completed | Phase 3 | Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy | June 26, 2012 | June 24, 2018 |
| NCT01560637 | Completed | Phase 3 | An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension | September 11, 2013 | August 12, 2021 |
| NCT01572077 | Completed | N/A | Rt Ventricular Substrate Metabolism as a Predictor of Rt Heart Failure in Patients With Pulmonary Arterial Hypertension | January 2011 | July 26, 2017 |
| NCT01588405 | Completed | Phase 2 | Remodulin® to Oral Treprostinil Transition | April 2012 | December 2014 |
| NCT01600898 | Completed | Screening of Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers | March 2012 | July 2016 | |
| NCT01607489 | Completed | N/A | Non-invasive Diagnostics of Pulmonary Hypertension With Dual Energy Computed Tomography | June 2011 | March 2017 |
| NCT05039086 | Completed | Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5 Inhibitors vs Endothelin Receptor Antagonist | September 1, 2021 | October 4, 2022 | |
| NCT01623492 | Completed | Eisenmenger Quality Enhancement Research Initiative | July 1, 2012 | April 17, 2018 | |
| NCT04994860 | Completed | Phase 1 | Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Sildenafil | March 22, 2018 | June 7, 2018 |
| NCT01642407 | Completed | Phase 4 | Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension | August 24, 2012 | March 12, 2018 |
| NCT04994119 | Completed | Phase 1 | Effect of BIA 5-1058 400 mg on Warfarin Pharmacokinetics | February 23, 2018 | May 23, 2018 |
| NCT01647945 | Completed | Phase 2 | FK506 (Tacrolimus) in Pulmonary Arterial Hypertension | July 2012 | August 2014 |
| NCT04991207 | Completed | Phase 1 | Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Bosentan | February 6, 2018 | May 14, 2018 |
| NCT01659411 | Completed | Adult Congenital Heart Disease Registry (QuERI) | December 1, 2011 | May 16, 2018 | |
| NCT00159874 | Completed | Phase 3 | A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children | January 2004 | December 2012 |
| NCT04991181 | Completed | Phase 1 | Absorption, Distribution, Metabolism and Excretion of BIA 5-1058 | March 31, 2017 | May 24, 2017 |
| NCT01721564 | Completed | N/A | Bosentan and Pulmonary Endothelial Function | April 2006 | December 2009 |
| NCT04991155 | Completed | Phase 1 | Effect of Food on BIA 5-1058 | July 20, 2015 | September 22, 2015 |
| NCT04908397 | Completed | Phase 1 | Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension | September 29, 2021 | June 30, 2023 |
| NCT01743001 | Completed | Phase 3 | Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome | May 21, 2013 | December 1, 2016 |
| NCT01757808 | Completed | Phase 1 | A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension | August 2011 | January 2015 |
| NCT01781052 | Completed | Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients | September 11, 2013 | January 16, 2017 | |
| NCT04903730 | Completed | Phase 1 | Safety, Tolerability, & Pharmacokinetics Study of Single & Multiple Inhaled Doses of Imatinib Inhalation Solution | May 24, 2021 | December 2, 2022 |
| NCT01798849 | Completed | Phase 1 | A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001) | March 15, 2013 | July 17, 2013 |
| NCT01799473 | Completed | Tyvaso Dosing and Titration Evaluation: TyTRATE Registry | January 2013 | December 2014 | |
| NCT04884971 | Completed | Phase 1 | Microbiota Transplant Therapy for Pulmonary Arterial Hypertension: Early Safety and Feasibility Study | November 3, 2021 | December 31, 2023 |
| NCT01829672 | Completed | N/A | Non-invasive Diagnostics of Pulmonary Hypertension With Dual Energy Computed Tomography | March 2013 | March 2017 |
| NCT01841762 | Completed | Phase 3 | Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument | April 1, 2013 | November 1, 2015 |
| NCT04808830 | Completed | Prevalence of Musculoskeletal Pain and Its Impact on Quality of Life and Functional Exercise Capacity in Patients With Pulmonary Arterial Hypertension | March 25, 2021 | June 15, 2021 | |
| NCT01847352 | Completed | N/A | Iron Status and Hypoxic Pulmonary Vascular Responses | February 2013 | April 2014 |
| NCT04787445 | Completed | Effects of Pulmonary Hypertension Therapy in Atypical Pulmonary Arterial Hypertension | March 11, 2021 | November 21, 2023 | |
| NCT01864863 | Completed | Phase 1 | To Compare the Pharmacokinetics of Traclear 62.5 mg Tablets and HGP1206 125mg 1 Tablet in Healthy Male Volunteers | April 2013 | May 2013 |
| NCT04712669 | Completed | Phase 2 | A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (ELEVATE 2) | March 15, 2021 | August 28, 2023 |
| NCT01908699 | Completed | Phase 3 | Beraprost-314d Added-on to Tyvaso® (BEAT) | May 31, 2013 | February 19, 2019 |
| NCT01926509 | Completed | Phase 1 | Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005) | November 14, 2013 | September 8, 2014 |
| NCT01934582 | Completed | Phase 3 | A Pharmacokinetic Substudy of the TDE-PH-304 Protocol | August 2013 | November 2013 |
| NCT04675944 | Completed | Phase 1 | Effect of BIA 5-1058 on the Steady State Pharmacokinetics of Treprostinil | February 28, 2018 | May 25, 2018 |
| NCT01959815 | Completed | Novel Screening Strategies for Scleroderma PAH | September 26, 2013 | November 6, 2019 | |
| NCT01966302 | Completed | Phase 2 | Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH) | November 2013 | June 2, 2019 |
| NCT02000856 | Completed | N/A | BEET PAH: a Study to Assess the Effects of Beetroot Juice in Patients With Pulmonary Arterial Hypertension | November 2013 | February 2015 |
| NCT04663230 | Completed | Right Atrial Fibrosis in Pulmonary Hypertension | April 30, 2021 | November 30, 2023 | |
| NCT02028299 | Completed | N/A | Estimation of Pulmonary Vascular Resistance by Contrast Echocardiography | April 2010 | July 2012 |
| NCT02032836 | Completed | Phase 1/Phase 2 | Comparative PK PD Study in PAH Patients (Fox vs. I-Neb) | March 10, 2014 | September 29, 2017 |
| NCT02036970 | Completed | Phase 2 | Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT | May 31, 2014 | May 16, 2018 |
| NCT04576988 | Completed | Phase 3 | A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR) | January 25, 2021 | December 6, 2022 |
| NCT02074449 | Completed | Study Of Right Ventricular Performance In PAH Patients Treated With Rapid Dose Treprostinil (Remodulin) | December 2012 | December 2015 | |
| NCT02080533 | Completed | Phase 1/Phase 2 | Feasibility of Slow-paced Respiration Therapy for Treatment of a Symptom Cluster in Pulmonary Arterial Hypertension | February 2014 | March 2016 |
| NCT02112487 | Completed | Phase 3 | Extension of the Psychometric Validation Study ORCHESTRA in Patients With PAH | June 23, 2014 | September 19, 2018 |
| NCT02126943 | Completed | OPsumit USers Registry | April 30, 2014 | April 24, 2020 | |
| NCT04567602 | Completed | A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or Selexipag | October 6, 2020 | March 5, 2024 | |
| NCT02234141 | Completed | Phase 2 | Selonsertib in Adults With Pulmonary Arterial Hypertension | November 2014 | December 2016 |
| NCT00303459 | Completed | Phase 4 | Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH) | May 2006 | December 2013 |
| NCT04505137 | Completed | Phase 1 | A Study to Investigate Safe and Tolerable Dose of GMA301 Injection in Healthy Volunteers | September 2, 2020 | March 19, 2021 |
| NCT02279160 | Completed | Phase 2 | Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension | December 2014 | June 2017 |
| NCT02279745 | Completed | Phase 2 | Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension | July 8, 2015 | March 29, 2021 |
| NCT04483115 | Completed | Phase 2 | Acute Haemodynamic Study of TPN171H in Patients With Pulmonary Arterial Hypertension | November 16, 2020 | June 29, 2022 |
| NCT02304198 | Completed | Phase 2/Phase 3 | Clinical Trial to Evaluate the Long-term Safety of Udenafil in Patient With PAH | April 2014 | February 2016 |
| NCT02310672 | Completed | Phase 4 | REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension | June 1, 2015 | September 10, 2019 |
| NCT02318186 | Completed | Pharmacokinetic Study of Sub-q and IV Treprostinil in Kids With Pulmonary Arterial Hypertension (PAH) | October 2013 | August 1, 2017 | |
| NCT02371733 | Completed | N/A | Aerobic Exercise Training in Pulmonary Arterial Hypertension | April 2015 | April 2018 |
| NCT02391441 | Completed | Ventricular Reversed Remodeling After LTX in PAH Patients | March 2015 | August 2019 | |
| NCT04316143 | Completed | Phase 2 | Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH | June 6, 2019 | October 20, 2021 |
| NCT02471183 | Completed | Phase 3 | Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension | October 12, 2015 | December 5, 2016 |
| NCT02484807 | Completed | Effect of Pharmacologic Interaction Between ERAs and PDE-5 Inhibitors on Medication Serum Levels and Clinical Disease Status in Patients With PAH | May 2015 | December 2016 | |
| NCT04282434 | Completed | DNA Methylation Dynamics Underlying Arterial Remodeling in PAH Patients: CLEOPAHTRA Clinical Trial | June 14, 2019 | October 14, 2020 | |
| NCT04280523 | Completed | Phase 2 | TranspulmonarY Estrogen Gradient and Estrogen Receptors (TYEGER) in PAH | January 5, 2021 | December 31, 2023 |
| NCT02558231 | Completed | Phase 3 | The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension | May 1, 2016 | April 20, 2020 |
| NCT00319020 | Completed | Phase 3 | Bosentan in Children With Pulmonary Arterial Hypertension Extension Study | August 23, 2005 | October 28, 2011 |
| NCT02631421 | Completed | Dysregulation of Lipid Metabolism and Right Ventricular Function in PAH | January 2015 | June 2019 | |
| NCT04104490 | Completed | Angiotensin Converting Enzyme (ACE2), Brain, Gut Dysbiosis in Pulmonary Hypertension | June 6, 2015 | December 31, 2021 | |
| NCT02664558 | Completed | Phase 2 | A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) | April 2016 | January 2018 |
| NCT02676947 | Completed | Phase 2 | A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension | January 2016 | February 18, 2018 |
| NCT00319267 | Completed | Phase 3 | Bosentan in Children With Pulmonary Arterial Hypertension | May 2005 | February 2007 |
| NCT04086537 | Completed | BMPR2 Mutations and Iron Metabolism in Pulmonary Arterial Hypertension | May 2, 2019 | February 28, 2021 | |
| NCT02734953 | Completed | Phase 2 | Effect of iNO on Invasively Derived Pulmonary Pressures in Patients With PAH | April 2016 | December 2016 |
| NCT04076241 | Completed | N/A | Effects of Adding Yoga Respiratory Training to Osteopathic Manipulative Treatment in Pulmonary Arterial Hypertension | September 7, 2019 | April 2, 2020 |
| NCT02746237 | Completed | Phase 1 | Single and Multiple Ascending Doses Clinical Pharmacology Study With KAR5585 | November 2015 | August 2016 |
| NCT02763735 | Completed | Right Ventricular Metabolism in Pulmonary Arterial Hypertension | June 2014 | June 2019 | |
| NCT04041648 | Completed | Phase 1 | Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606 | November 9, 2018 | May 12, 2020 |
| NCT02799771 | Completed | HYPID (Pulmonary Hypertension in Interstitial Lung Disease) EXTENSION | February 2013 | February 2022 | |
| NCT03950739 | Completed | Phase 1 | Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso | September 17, 2019 | August 22, 2023 |
| NCT02800941 | Completed | Bleeding Frequency Under Anticoagulant Treatment in Pulmonary Hypertension | July 5, 2017 | September 5, 2023 | |
| NCT00323297 | Completed | Phase 4 | Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension | September 2006 | August 2013 |
| NCT02847260 | Completed | Phase 4 | Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID) | April 2012 | March 2014 |
| NCT02858791 | Completed | MIF- Thyroxine Interactions in the Pathogenesis of Pulmonary Arterial Hypertension | February 2013 | December 21, 2017 | |
| NCT03926793 | Completed | Phase 1 | Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension | February 4, 2020 | May 5, 2021 |
| NCT02885155 | Completed | Contribution of Echocardiography to Prognostic Evaluation of Pulmonary Arterial Hypertension | January 2007 | January 2012 | |
| NCT03889509 | Completed | A Systematic Review of Factors Associated With Pulmonary Arterial Hypertension in Systemic Sclerosis | March 1, 2018 | March 1, 2021 | |
| NCT02891850 | Completed | Phase 4 | Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy | January 11, 2017 | March 3, 2020 |
| NCT03888365 | Completed | Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH | April 1, 2019 | September 19, 2019 | |
| NCT05564637 | Enrolling by invitation | Phase 2 | A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension | March 13, 2023 | June 2024 |
| NCT06445673 | Enrolling by invitation | A Prospective Non-interventional Observational Study to Observe Long-term Treatment and Outcomes in Pulmonary Arterial Hypertension (PAH) Patients | June 2024 | June 2030 | |
| NCT04930289 | Enrolling by invitation | Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs | October 15, 2021 | December 30, 2025 | |
| NCT03683186 | Enrolling by invitation | Phase 3 | A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | September 23, 2019 | September 2024 |
| NCT05618093 | Enrolling by invitation | N/A | Non-Invasive Measurement of Cardiac Output and Stroke Volume in PAH/CTEPH | March 2, 2023 | December 31, 2025 |
| NCT00878943 | No longer available | Open Label Access Study Of Sildenafil In Adult Patients With Pulmonary Arterial Hypertension Completing A1481244 Study | |||
| NCT01897740 | No longer available | Sildenafil Therapy For Subjects Who Derive Clinical Benefit From Continued Treatment With Sildenafil | |||
| NCT01582438 | No longer available | An Open Label Access Study For Subjects Who Completed A1481156 | |||
| NCT00866983 | No longer available | Local Open-Label Access Study For Patients Who Completed A1481244 Study In Brazil | |||
| NCT04570228 | Not yet recruiting | N/A | TROPHY PAH Pivotal Study - TReatment of Pulmonary HYpertension for PAH Pivotal Study | January 1, 2023 | December 1, 2025 |
| NCT06274801 | Not yet recruiting | Phase 3 | Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) | June 2024 | December 2026 |
| NCT06176118 | Not yet recruiting | Phase 2 | Clinical Trial of 2-HOBA in Pulmonary Arterial Hypertension | August 1, 2024 | July 2026 |
| NCT05977933 | Not yet recruiting | Assessing the Utility of Submaximal CPET in Treatment Management of PAH | April 1, 2024 | December 30, 2024 | |
| NCT06384534 | Not yet recruiting | N/A | Exercise Performance on Ambient Air vs. Low-Flow Oxygen Therapy in Pulmonary Vascular Disease (PVD) | May 2024 | November 2025 |
| NCT06409026 | Not yet recruiting | Phase 4 | Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension | July 2024 | February 2025 |
| NCT06429930 | Not yet recruiting | Phase 1 | Safety, Tolerability and Pharmacokinetics Study of L608 in Healthy Adults | September 1, 2024 | September 30, 2025 |
| NCT06350032 | Not yet recruiting | Phase 3 | Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH | May 2024 | November 2028 |
| NCT05655481 | Not yet recruiting | N/A | Telerehabilitation Program Via Videoconference PAH - Randomized Clinical Trial | January 15, 2023 | May 10, 2025 |
| NCT06351345 | Not yet recruiting | Phase 2 | 129 Xenon Imaging in Patients Treated With Sotatercept | June 1, 2024 | August 1, 2025 |
| NCT05641675 | Not yet recruiting | Non-invasive Pulmonary Artery Prediction (ADOPTS) | February 1, 2023 | October 1, 2023 | |
| NCT05624242 | Not yet recruiting | Assessment of Right Ventricular Function by Cardiac MRI in Patients With Pulmonary Arterial Hypertension (IRMA) | February 1, 2023 | December 1, 2023 | |
| NCT06072937 | Not yet recruiting | N/A | IntelliStent for Pulmonary Flow Adjustment in Congenital Heart Disease and Dilated Cardiomyopathy | June 4, 2024 | June 4, 2026 |
| NCT04915300 | Not yet recruiting | Phase 2 | Apabetalone for Pulmonary Arterial Hypertension | October 2023 | March 2025 |
| NCT05660863 | Not yet recruiting | Phase 1 | A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of MN-08 Tablets | May 31, 2024 | December 1, 2025 |
| NCT06104228 | Not yet recruiting | Phase 2 | 129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH) | July 1, 2024 | March 31, 2026 |
| NCT04254289 | Not yet recruiting | N/A | Pilot Randomized Trial of Ambulatory Exercise in Pulmonary Hypertension | June 2024 | December 2025 |
| NCT06172790 | Not yet recruiting | N/A | The Effects of the Otago Exercise Program | February 1, 2024 | February 1, 2026 |
| NCT06454838 | Recruiting | Exercise Capacity Muscle Oxygenation and Arterial Stiffness in Children With Pulmonary Arterial Hypertension | April 30, 2024 | December 30, 2024 | |
| NCT01397110 | Recruiting | N/A | Respiratory and Physical Therapy in Patients With Associated Pulmonary Arterial Hypertension (APAH) With Congenital Heart Defects | January 2012 | December 2025 |
| NCT01712620 | Recruiting | Phase 2 | Spironolactone for Pulmonary Arterial Hypertension | January 10, 2014 | December 31, 2024 |
| NCT02249923 | Recruiting | Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry | October 2014 | December 2031 | |
| NCT02579954 | Recruiting | N/A | Cardiac Function and Exercise Capacity in Pulmonary Arterial Hypertension | August 6, 2015 | June 2024 |
| NCT02691689 | Recruiting | N/A | Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions | November 2015 | February 2025 |
| NCT02845518 | Recruiting | N/A | Study of Cardiac MRI in the Follow up Assessment of Patients With PAH (EVITA) | February 16, 2017 | May 16, 2024 |
| NCT02932410 | Recruiting | Phase 3 | A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) | October 24, 2017 | December 31, 2024 |
| NCT03554330 | Recruiting | N/A | Combined Use of Radiofrequency-ablation and Balloon-septostomy in the Creation of a Stable Inter-atrial Communication | July 12, 2018 | December 30, 2022 |
| NCT03626688 | Recruiting | Phase 3 | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | August 30, 2018 | December 2024 |
| NCT03782818 | Recruiting | Phase 1/Phase 2 | Olaparib for PAH: a Multicenter Clinical Trial | November 20, 2019 | March 2024 |
| NCT03838445 | Recruiting | N/A | Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH) | February 14, 2020 | December 31, 2026 |
| NCT03954405 | Recruiting | Multi-marker Approach for Risk Assessment in PAH | November 1, 2017 | December 30, 2025 | |
| NCT03959748 | Recruiting | DataBase of pulmoNary hyPertesion in PoLish Population - BNP-PL | March 1, 2018 | February 28, 2028 | |
| NCT04071327 | Recruiting | Pulmonary Hypertension Association Registry | October 2015 | October 2025 | |
| NCT04207593 | Recruiting | Phase 2 | The Effect of Oxygen Therapy on 6MWD in PAH and CTEPH Patients With Hypoxemia | April 1, 2019 | December 2022 |
| NCT04266197 | Recruiting | Phase 2 | Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study | September 25, 2020 | December 31, 2024 |
| NCT04273945 | Recruiting | Phase 3 | Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension | June 30, 2020 | February 20, 2029 |
| NCT04278404 | Recruiting | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | March 5, 2020 | July 2024 | |
| NCT04451850 | Recruiting | HRV as a Marker of Treatment Response in PAH Arterial Hypertension | June 1, 2021 | June 30, 2024 | |
| NCT04555161 | Recruiting | N/A | Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System | March 15, 2021 | October 2026 |
| NCT04691154 | Recruiting | Phase 3 | A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD | August 1, 2021 | July 31, 2025 |
| NCT04778046 | Recruiting | Phase 2 | Pulmonary Hypertension SOLAR | November 8, 2023 | December 30, 2024 |
| NCT04796337 | Recruiting | Phase 3 | A Long-term Follow-up Study of Sotatercept for PAH Treatment (MK-7962-004/A011-12) | May 12, 2021 | November 30, 2027 |
| NCT04808596 | Recruiting | Pulmonary Hypertension Biorepository and Registry | August 10, 2020 | July 31, 2026 | |
| NCT04811092 | Recruiting | Phase 3 | Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13) | March 18, 2022 | December 27, 2029 |
| NCT04816604 | Recruiting | Phase 2 | Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) | April 5, 2021 | December 2027 |
| NCT04968210 | Recruiting | Metabolic Remodeling in Pulmonary Arterial Hypertension (PAH) | May 27, 2022 | December 2024 | |
| NCT04972656 | Recruiting | N/A | Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension | September 5, 2022 | March 30, 2026 |
| NCT04991454 | Recruiting | Phase 2 | Xenon MRI Pulm Hypertension | September 1, 2021 | August 30, 2026 |
| NCT05036135 | Recruiting | Phase 2/Phase 3 | A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH) | December 2, 2021 | January 2025 |
| NCT05147805 | Recruiting | Phase 2 | A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension | August 24, 2022 | March 31, 2024 |
| NCT05167825 | Recruiting | Phase 3 | A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension | November 14, 2022 | March 17, 2025 |
| NCT05179356 | Recruiting | Phase 2 | Dapagliflozin in Pulmonary Arterial Hypertension | January 1, 2023 | September 2024 |
| NCT05203510 | Recruiting | Phase 4 | A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension | August 10, 2022 | September 12, 2024 |
| NCT05224531 | Recruiting | Phase 2 | Effect of CS1 in Subjects With Pulmonary Arterial Hypertension | May 5, 2022 | September 2024 |
| NCT05339386 | Recruiting | Developing Hyperpolarized 129Xe MRI Biomarkers for Evaluation of Pulmonary Arterial Hypertension | August 29, 2022 | March 31, 2025 | |
| NCT05368467 | Recruiting | National Registry and Cohort Study of Pulmonary Vascular Disease | March 29, 2022 | May 30, 2028 | |
| NCT05413109 | Recruiting | N/A | COMPression of Left Main coRonary artEry in patientS With Pulmonary Arterial Hypertension aSymptomatIc fOr aNgina | May 15, 2022 | May 15, 2026 |
| NCT05452889 | Recruiting | Early Phase 1 | PET Image in PAH Patients | January 31, 2023 | December 2025 |
| NCT05464095 | Recruiting | N/A | The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study | September 1, 2022 | August 1, 2027 |
| NCT05557942 | Recruiting | Phase 3 | Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL) | November 2, 2022 | December 31, 2025 |
| NCT05566002 | Recruiting | Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension | June 1, 2022 | December 31, 2024 | |
| NCT05569655 | Recruiting | N/A | Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With RHF Caused by PAH | April 6, 2021 | December 31, 2022 |
| NCT05587400 | Recruiting | N/A | Consistency of Electrical Cardiometry and Pulmonary Artery Catheter | July 27, 2022 | December 31, 2024 |
| NCT05587712 | Recruiting | Phase 2 | Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008) | January 19, 2023 | September 21, 2028 |
| NCT05600218 | Recruiting | RWD Patients With Pulmonary Arterial Hypertension Treated With IP Prostacyclin Receptor Agonists | June 1, 2021 | December 31, 2024 | |
| NCT05622695 | Recruiting | Non-invasive Pulmonary Artery Prediction | October 30, 2022 | August 31, 2023 | |
| NCT05649748 | Recruiting | Phase 2/Phase 3 | An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) | March 7, 2023 | December 31, 2026 |
| NCT05665556 | Recruiting | REgistry of Pulmonary Arterial Hypertension Associated With CONNECTIVE Tissue Diseases (RECONNECTIVE) | December 15, 2022 | December 2027 | |
| NCT05679570 | Recruiting | Phase 2 | Satralizumab in the Treatment of Pulmonary Arterial Hypertension (SATISFY-JP Trial) | July 12, 2022 | June 30, 2026 |
| NCT05745961 | Recruiting | Quantifying 18kDa TSPO Expression in the Lung in Pulmonary Artery Hypertension (PAH) | February 1, 2023 | April 2025 | |
| NCT05825417 | Recruiting | Phase 4 | Pulmonary Hypertension: Intensification and Personalisation of Combination Rx | June 14, 2023 | January 2026 |
| NCT05828147 | Recruiting | Phase 4 | Anti-CD20 Antibodies for Treatment of SLE-PAH | May 25, 2023 | March 2026 |
| NCT05934526 | Recruiting | Phase 3 | Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) | December 28, 2023 | October 2025 |
| NCT05938946 | Recruiting | Phase 1 | Safety, Tolerability and Pharmacokinetics of L608 in Healthy Adults | August 30, 2023 | June 30, 2024 |
| NCT05968859 | Recruiting | N/A | A Study of Pulmonary Hypertension Peripheral Limitations | January 2, 2024 | July 2028 |
| NCT05975905 | Recruiting | Phase 2 | A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study). | October 17, 2023 | January 31, 2027 |
| NCT06053580 | Recruiting | Phase 2 | Repurposing Valsartan May Protect Against Pulmonary Hypertension | February 28, 2024 | July 1, 2027 |
| NCT06137742 | Recruiting | Phase 1 | A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension | November 17, 2023 | September 18, 2026 |
| NCT06196801 | Recruiting | Efficacy of Triple-Combination Therapy in Severe PAH-CHD | June 17, 2022 | December 1, 2025 | |
| NCT06317805 | Recruiting | Phase 4 | Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients | December 6, 2023 | June 30, 2027 |
| NCT06405126 | Recruiting | Validation of a Machine Learning Predictive Model to Distinguish Post-capillary Pulmonary Hypertension | February 21, 2024 | February 2026 | |
| NCT04791514 | Terminated | Phase 2 | A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH) | March 29, 2022 | August 26, 2022 |
| NCT02525926 | Terminated | N/A | Pulmonary Artery Denervation for Treatment of Pulmonary Arterial Hypertension | January 2016 | March 2018 |
| NCT00723554 | Terminated | Phase 3 | Iloprost Power Disc-15 in Pulmonary Arterial Hypertension | July 2008 | April 2011 |
| NCT01302444 | Terminated | Phase 4 | Treprostinil Combined With Tadalafil for Pulmonary Hypertension | March 2011 | March 2012 |
| NCT02507011 | Terminated | Phase 2 | Beta-blockers in Pulmonary Arterial Hypertension | January 31, 2016 | July 1, 2019 |
| NCT04435782 | Terminated | Phase 4 | A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging | July 7, 2021 | July 28, 2023 |
| NCT00722254 | Terminated | Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder | June 2006 | February 2009 | |
| NCT02284737 | Terminated | Phase 4 | A Study to Investigate the Efficacy of PADN to Improved Functional Capacity and Hemodynamics in Patients With PAH | November 28, 2014 | July 30, 2021 |
| NCT02253394 | Terminated | Phase 4 | The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study | September 2015 | February 2018 |
| NCT02081690 | Terminated | Phase 3 | A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain | March 1, 2014 | November 1, 2015 |
| NCT02060487 | Terminated | Phase 4 | Effects of Oral Sildenafil on Mortality in Adults With PAH | September 22, 2014 | February 26, 2021 |
| NCT01934647 | Terminated | Phase 1 | Acute Dosing of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-003) | November 22, 2013 | September 8, 2014 |
| NCT00706082 | Terminated | Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc) | October 2008 | March 2012 | |
| NCT01847716 | Terminated | Transforming Growth Factor Beta Signalling in the Development of Muscle Weakness in Pulmonary Arterial Hypertension | October 2013 | August 2016 | |
| NCT01244620 | Terminated | Phase 1 | A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses | November 2010 | December 2010 |
| NCT01179737 | Terminated | Phase 2 | Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH) | July 2010 | January 2013 |
| NCT01847014 | Terminated | Phase 3 | Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument | September 1, 2013 | November 30, 2017 |
| NCT01835080 | Terminated | Obstructive Sleep Apnea (OSA) in Pulmonary Arterial Hypertension (PAH) | April 2013 | March 2014 | |
| NCT01795950 | Terminated | Phase 1 | Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH) | April 2013 | January 2016 |
| NCT01739400 | Terminated | Phase 3 | Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome | September 10, 2013 | January 12, 2018 |
| NCT01725269 | Terminated | Phase 2 | Long-term Study of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension Who Completed AIR001-CS05 | March 2013 | April 2014 |
| NCT01725256 | Terminated | Phase 2 | A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH) | November 2012 | February 2014 |
| NCT04955990 | Terminated | Phase 4 | A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants | October 14, 2021 | December 20, 2022 |
| NCT01117987 | Terminated | Phase 3 | Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH) | April 2010 | April 2014 |
| NCT04991194 | Terminated | Phase 1 | Effect of Age-gender on the Pharmacokinetic and Pharmacodynamic Profiles of BIA 5 1058 | October 12, 2015 | December 30, 2016 |
| NCT01094067 | Terminated | Phase 2 | Tezosentan in Patients With Pulmonary Arterial Hypertension | September 1, 2010 | September 1, 2011 |
| NCT01077297 | Terminated | Phase 2 | Tezosentan in Pulmonary Arterial Hypertension | August 2010 | September 2011 |
| NCT00439946 | Terminated | Phase 4 | Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH | February 2007 | March 2011 |
| NCT00995566 | Terminated | A Non-Interventional, Patient Registry For The Collection Of Pre-Defined Safety Data In Patients Prescribed Thelin | April 2010 | February 2011 | |
| NCT01494896 | Terminated | Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching | November 2011 | December 2014 | |
| NCT01433328 | Terminated | Phase 4 | Lidocaine Subcutaneous Infusion for Control of Treprostinil Related Site Pain | January 2012 | April 2012 |
| NCT00902603 | Terminated | Ventavis® Registry Protocol | March 2009 | February 2014 | |
| NCT00832507 | Terminated | Phase 2 | Study of Cicletanine for Pulmonary Arterial Hypertension (PAH) | January 2009 | March 2012 |
| NCT01392495 | Terminated | Phase 3 | Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH) | June 2011 | March 2014 |
| NCT01357746 | Terminated | Phase 1 | Measuring Blood Pressure in the Lung Circulation With Sonar Technology (Echo-Doppler) | July 2011 | |
| NCT03251872 | Terminated | Early Phase 1 | Olaparib for PAH: a Pilot Study | October 25, 2018 | December 1, 2019 |
| NCT00494533 | Terminated | Phase 4 | Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension | March 2005 | October 2005 |
| NCT03556020 | Terminated | Phase 2 | Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH | July 15, 2018 | January 7, 2022 |
| NCT00811018 | Terminated | Phase 3 | A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension | March 2003 | July 2011 |
| NCT03657095 | Terminated | Phase 3 | A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension | December 10, 2018 | July 20, 2019 |
| NCT02968901 | Terminated | Phase 4 | Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA) | September 1, 2015 | September 10, 2018 |
| NCT02939599 | Terminated | Phase 2 | Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients | February 1, 2018 | November 6, 2018 |
| NCT02927366 | Terminated | Phase 2 | Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients | September 19, 2017 | June 7, 2018 |
| NCT03795428 | Terminated | Phase 2 | Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004 | April 10, 2019 | January 11, 2022 |
| NCT00796666 | Terminated | Phase 3 | Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil | May 2009 | March 2011 |
| NCT02899533 | Terminated | [18F]FES PET/CT in PAH | July 2016 | April 6, 2021 | |
| NCT03884465 | Terminated | Phase 2 | Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil | November 11, 2019 | December 23, 2020 |
| NCT02885012 | Terminated | Phase 4 | Crossover Study From Macitentan or Bosentan Over to Ambrisentan | June 2016 | July 7, 2017 |
| NCT03924154 | Terminated | Phase 2 | A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1) | August 1, 2019 | February 24, 2020 |
| NCT01319045 | Terminated | N/A | Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease | June 2011 | May 2013 |
| NCT00430716 | Terminated | Phase 4 | To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension. | April 8, 2008 | May 25, 2010 |
| NCT00796510 | Terminated | Phase 3 | Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety | July 2010 | January 2011 |
| NCT02736149 | Terminated | Phase 2 | Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) | December 2016 | August 2018 |
| NCT04084678 | Terminated | Phase 3 | A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH | January 20, 2021 | April 12, 2023 |
| NCT02725372 | Terminated | Phase 3 | Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH | April 2016 | August 2018 |
| NCT04090866 | Terminated | Cardiac Metabolic Remodeling After Pulmonary Vasodilator Therapy in Pulmonary Arterial Hypertension: A Pilot Study | November 14, 2019 | July 21, 2020 | |
| NCT04125745 | Terminated | Phase 2 | Oral CXA-10 in Pulmonary Arterial Hypertension | October 31, 2019 | December 1, 2020 |
| NCT02583906 | Terminated | N/A | Sleep Disordered Breathing in Precapillary Pulmonary Hypertension: Effect of CPAP Treatment | April 2014 | May 2019 |
| NCT00795639 | Terminated | Phase 3 | Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS) | December 2008 | March 2011 |
| NCT03683082 | Unknown status | N/A | Oxygen Treatment and Pulmonary Arterial Hypertension | June 5, 2018 | June 30, 2019 |
| NCT04309838 | Unknown status | Observation Study With Implantable Medication Pump for Intravenous Treprostinil Therapy in Patients With Pulmonary Arterial Hypertension | March 2020 | December 2021 | |
| NCT03401476 | Unknown status | Phase 2 | Effect of Morphine on Dyspnea and 6-Minute Walk Distance in Pulmonary Arterial Hypertension | May 8, 2017 | December 31, 2019 |
| NCT04450862 | Unknown status | N/A | Anxiety Self-management Intervention for Pulmonary Hypertension | August 5, 2020 | August 30, 2021 |
| NCT03236818 | Unknown status | Phase 4 | Goal Oriented Strategy to Preserve Ejection Fraction Trial | May 2013 | September 2017 |
| NCT04489251 | Unknown status | Assessment of the TGF-beta Pathway and Micro-RNA in Pediatric Pulmonary Arterial Hypertension | July 1, 2020 | January 1, 2023 | |
| NCT04503733 | Unknown status | Phase 1 | A Study of GMA301 in Subjects With Pulmonary Arterial Hypertension | October 22, 2020 | June 10, 2023 |
| NCT02889315 | Unknown status | LenusPro Pump in PAH Treated With Treprostinil | November 2013 | December 2023 | |
| NCT04528056 | Unknown status | Phase 1/Phase 2 | Pilot Study of the Safety and Efficacy of Sulfasalazine in Pulmonary Arterial Hypertension | August 1, 2020 | October 31, 2022 |
| NCT02207868 | Unknown status | 3D Echo Evaluation of the Ventricles in Sclero Associated Severe PAH | June 2014 | December 2019 | |
| NCT03567668 | Unknown status | Surgical Valvuloplasty for Congenital Mitral Insufficiency | January 1, 2012 | December 31, 2018 | |
| NCT04650659 | Unknown status | Functional Exercise Tests in Patients With Systemic Sclerosis | July 27, 2021 | January 31, 2023 | |
| NCT02023450 | Unknown status | Early Phase 1 | Testing of HIV Protease Inhibitors to Suppress Inflammation and Improve Cardio Pulmonary Hemodynamics in Subjects With Pulmonary Arterial Hypertension | December 2013 | July 2015 |
| NCT04677608 | Unknown status | Pulmonary Hypertension Modality of Death and Validation of REVEAL Risk Score | July 21, 2020 | August 31, 2022 | |
| NCT01907295 | Unknown status | National Cohort Study of Idiopathic and Heritable Pulmonary Arterial Hypertension | February 2014 | December 2022 | |
| NCT01905189 | Unknown status | N/A | Resynchronisation Therapy of Right Ventricle in Pulmonary Arterial Hypertension | July 2013 | June 2014 |
| NCT03051763 | Unknown status | The Effects of Commercial Air Travel on Patients Suffering From Pulmonary Hypertension | January 19, 2017 | May 19, 2022 | |
| NCT04241497 | Unknown status | N/A | Home-based Exercise Training in Patients With Pulmonary Arterial Hypertension: Effect on Skeletal Muscular Function and Metabolism | March 2020 | March 2021 |
| NCT03049995 | Unknown status | Stress Echo 2020 - The International Stress Echo Study | November 2016 | December 2021 | |
| NCT03045666 | Unknown status | N/A | Impact of Rehabilitation Program on PAH Patients Treated With Macitentan. | April 15, 2017 | May 1, 2018 |
| NCT00705588 | Unknown status | Phase 4 | Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids. | August 2008 | |
| NCT04053296 | Unknown status | Long-term Outcomes of Pregnant Women With PAH | November 1, 2017 | December 31, 2019 | |
| NCT01827059 | Unknown status | Phase 2 | Bosentan In Exercise Induced Pulmonary Arterial Hypertension in CongenitaL Heart diseasE | October 2013 | June 2018 |
| NCT03718780 | Unknown status | N/A | Assessment of Continuous Measurement of Transcutaneous CO2 for Evaluation of Alveolar Dead Space During Exercise | February 22, 2019 | February 22, 2024 |
| NCT03928002 | Unknown status | N/A | 4DFlow Magnetic Resonance Imaging in Patients With Pulmonary Hypertension Associated With Congenital Heart Disease | May 30, 2018 | October 1, 2020 |
| NCT01712997 | Unknown status | Phase 3 | Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Hypertension Patients | September 2012 | |
| NCT03933579 | Unknown status | The PAH Platform for Deep Phenotyping in Korean Subjects | March 1, 2018 | December 31, 2020 | |
| NCT01649739 | Unknown status | Phase 4 | Vardenafil as add-on Therapy for Patients With Pulmonary Hypertension Treated With Inhaled Iloprost | September 2012 | January 2014 |
| NCT01637675 | Unknown status | Phase 2/Phase 3 | Efficacy and Safety Study of Sodium Tanshinone IIA Sulfonate on Pulmonary Hypertension | May 2013 | December 2014 |
| NCT02799979 | Unknown status | 3D Imaging: Prognostic Role in Pulmonary Arterial Hypertension | October 2014 | June 2019 | |
| NCT03810443 | Unknown status | N/A | Prevalence of the Hyperventilation Syndrome in Pulmonary Arterial Hypertension | January 14, 2019 | July 14, 2021 |
| NCT03819777 | Unknown status | Volatile Organic Compounds (VOCs) as a Biomarker in Immune-mediated Pulmonary Arterial Hypertension (PAH) | March 1, 2018 | January 31, 2023 | |
| NCT00617487 | Unknown status | Pulmonary Arterial Hypertension in Systemic Sclerosis | December 2007 | January 2020 | |
| NCT01457170 | Unknown status | N/A | Effects of Apelin on the Lung Circulation in Pulmonary Hypertension | January 2012 | January 2014 |
| NCT04062565 | Unknown status | Phase 3 | Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH | March 25, 2019 | December 2021 |
| NCT05343091 | Unknown status | Prognostic Value of the Right Ventricular Function by Portable Ultrasound in Patients With Pulmonary Hypertension. | March 1, 2021 | January 31, 2023 | |
| NCT01417338 | Unknown status | Registry for Pulmonary Hypertension in China | August 2009 | December 2020 | |
| NCT03841344 | Unknown status | N/A | Repeatability and Sensitivity to Change of Non-invasive Endpoints in PAH | September 15, 2015 | May 20, 2019 |
| NCT00544726 | Unknown status | N/A | Rehabilitation for Patients With Pulmonary Arterial Hypertension | February 2008 | |
| NCT05417373 | Unknown status | Algorithms to Diagnose Pulmonary Arterial Hypertension | January 17, 2019 | June 1, 2023 | |
| NCT02652429 | Unknown status | Phase 3 | Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH | March 2016 | December 2023 |
| NCT01383083 | Unknown status | Effects of Iloprost Treatment in Adult Patients With Pulmonary Arterial Hypertension Related to Congenital Heart Disease | November 2010 | November 2012 | |
| NCT00483626 | Unknown status | Phase 4 | Hemodynamic Response After Six Months of Sildenafil | August 2003 | June 2007 |
| NCT03977428 | Unknown status | Central China Congenital Heart Disease Associated Pulmonary Arterial Hypertension Cohort Study | January 1, 2019 | June 30, 2023 | |
| NCT02516722 | Unknown status | N/A | TReatment Of Pulmonary HYpertension 1 Study | February 2016 | June 2021 |
| NCT03476629 | Unknown status | N/A | Effects of Different Types of Physical Training in Patients With Pulmonary Arterial Hypertension. | January 10, 2016 | December 10, 2020 |
| NCT00625079 | Withdrawn | Phase 4 | Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil | February 2007 | December 2009 |
| NCT03016468 | Withdrawn | Phase 2 | Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH | May 2017 | September 2018 |
| NCT01615627 | Withdrawn | Phase 4 | Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain | July 1, 2012 | February 28, 2019 |
| NCT01557660 | Withdrawn | Phase 3 | Inhaled Treprostinil for PAH: Open-label Extension | June 2012 | December 2018 |
| NCT00453414 | Withdrawn | Phase 2 | Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension | July 2006 | October 2006 |
| NCT01458236 | Withdrawn | Phase 3 | A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor | November 2011 | March 2016 |
| NCT00593905 | Withdrawn | Pharmacogenomics in Pulmonary Arterial Hypertension | July 2005 | July 2012 | |
| NCT01251848 | Withdrawn | Phase 1 | Drug Interaction Between Ritonavir And Sitaxsentan | January 2011 | February 2011 |
| NCT03833323 | Withdrawn | Implantable System for Remodulin Post-Approval Study | August 1, 2020 | June 30, 2021 | |
| NCT01352026 | Withdrawn | Phase 2 | Evaluation of Metformin Activity in Addition to Conventional Treatment of Grade II or III Pulmonary Arterial Hypertension (PAH) | May 2011 | |
| NCT02782052 | Withdrawn | Phase 3 | Bronchodilator's Effects on Exertional Dyspnoea in Pulmonary Arterial Hypertension | July 2016 | February 2019 |
| NCT01508780 | Withdrawn | Phase 4 | Combined Use of Angiography, Optical Coherence Tomography and Intravascular Ultrasound in Evaluation of Pulmonary Vascular Structure and Function in Patients With Pulmonary Arterial Hypertension Treated With Oral Bosentan | May 2012 | February 2014 |
| NCT01792622 | Withdrawn | Patient Reported Outcomes in Pulmonary Arterial Hypertension | July 2013 | September 2013 | |
| NCT02999906 | Withdrawn | Phase 3 | Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension | October 2017 | June 2022 |
| NCT03602781 | Withdrawn | Phase 3 | Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric | August 2018 | June 2020 |
| NCT02882126 | Withdrawn | Phase 4 | An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension | June 2017 | June 2021 |
| NCT01251835 | Withdrawn | Phase 1 | Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan | December 2010 | January 2011 |
| NCT02958358 | Withdrawn | N/A | FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan | September 2014 | September 2016 |
| NCT01645826 | Withdrawn | N/A | Efficacy Study of Cardizem in Pulmonary Arterial Hypertension | July 2012 | September 2014 |
| NCT01880866 | Withdrawn | Phase 1 | (-)-Epicatechin and Pulmonary Arterial Hypertension | July 2013 | January 2014 |
| NCT00625469 | Withdrawn | Phase 4 | Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan | October 2007 | December 2009 |
| NCT03905083 | Withdrawn | N/A | miRNA and Myokines in Patients With PAH | December 2021 | June 15, 2023 |
| NCT02436512 | Withdrawn | Phase 3 | Study to Assess Acute Vasodilation Response of Inhaled Nitric Oxide | June 2015 | August 2015 |
| NCT02309463 | Withdrawn | Correlation of LONGterm Wrist ACTigraphy Recorded Physical Performance & 6-minute Walk Distance in Patients With Pulmonary Arterial Hypertension | January 2015 | February 2017 | |
| NCT01557647 | Withdrawn | Phase 3 | Safety and Efficacy of Inhaled Treprostinil in Patients With PAH | June 2012 | June 2016 |
| NCT01723371 | Withdrawn | Phase 1/Phase 2 | Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children | September 2012 | |
| NCT02893995 | Withdrawn | Phase 4 | Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension | February 2017 | April 2018 |
| NCT03789643 | Withdrawn | Phase 2 | Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension | March 2019 | June 2021 |
- HPO alt_id (Human Phenotype Ontology)
- HP:0006546
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0002092
- OrphaNumber from OrphaNet (Orphanet)
- 182090